Drugs / Leflutrozole
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT07571928 | May 2026 → May 2027 expected | azoospermia | Martin Blomberg Jensen | Not yet recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06993155 | Jun 2025 → Jul 2026 overdue | spermatogenic failure 96 | ReproNovo Aps | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Leflutrozole | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06993155 ↗ |
| Route | Oral | “Leflutrozole, 0.05 mg, oral capsule, once weekly for 16 weeks” NCT06993155 ↗ |